Extensively drug-resistant tuberculosis in South Korea: Risk factors and treatment outcomes among patients at a tertiary referral hospital

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 42-49

  Jeon, Christie Y ^a,b   Soo, Hee Hwang ^c   Jin, Hong Min ^c   Prevots, D Rebecca ^b   Goldfeder, Lisa C ^b   Lee, Hyeyoung ^e   Seok, Yong Eum ^d   Doo, Soo Jeon ^c   Hyung, Seok Kang ^c   Jin, Hee Kim ^c   Byoung, Ju Kim ^c   Dae, Yeon Kim ^c   Holland, Steven M ^b   Seung, Kyu Park ^c,d   Sang, Nae Cho ^f   Barry III, Clifton E ^b   Via, Laura E ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c National Masan Hospital   (South Korea)

^d International Tuberculosis Research Center   (South Korea)

^e Yonsei University Wonju   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SOUTH KOREA; SPUTUM CULTURE; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FLUOROQUINOLONES; HUMANS; KOREA; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 39349102716     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/524017     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
2. Masjedi MR, Farnia P, Sorooch S, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006; 43:841-7.
3. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
4. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81:430-2.
5. Annual report on the notified tuberculosis patients in Korea. Bulgwangdong, Seoul, South Korea: Korean Center for Disease Control and Prevention, Korean Institute for Tuberculosis, 2005.
6. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998; 2:27-36.
7. Hong YP, Kim SJ, Lew WJ, Lee SH, Lee EK. Cohort analyses of the treatment of smear-positive pulmonary tuberculosis patients under programme conditions in Korea, 1983-1994. Int J Tuberc Lung Dis 1998; 2:365-71.
8. World Health Organization. WHO report 2006: global tuberculosis control. Geneva: World Health Organization, 2005.
9. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis 2003; 7:912-9.
10. Korean National Tuberculosis Association. Transition of initial drug resistance in Korea based on surveillance (11 drugs) 1994, 1998, 2003. Seoul, South Korea: Korean National Tuberculosis Association, 2007. Available at: http://www.knta.or.kr/english/statistics/statistics01_3.asp. Accessed 21 November 2007.
11. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5:887-93.
12. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41:21-43.
13. Wayne LG. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis 1974; 109:147-51.
14. Chiang CY, Chang CT, Chang RE, Li CT, Huang RM. Patient and health system delays in the diagnosis and treatment of tuberculosis in southern Taiwan. Int J Tuberc Lung Dis 2005; 9:1006-12.
15. Long NH, Johansson E, Lonnroth K, Eriksson B, Winkvist A, Diwan VK. Longer delays in tuberculosis diagnosis among women in Vietnam. Int J Tuberc Lung Dis 1999; 3:388-93.
16. Park S, Soumerai SB, Adams AS, Finkelstein JA, Jang S, Ross-Degnan D. Antibiotic use following a Korean national policy to prohibit medication dispensing by physicians. Health Policy Plan 2005; 20:302-9.
17. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8:361-8.
18. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61:903-8.
19. Yoon YS, Lee HJ, Yoon HI, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005; 9:1215-9.
20. Tupasi TE, Quelapio MI, Orillaza RB, et al. DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed. Tuberculosis (Edinb) 2003; 83:52-8.
21. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365:318-26.
22. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33:167-75.
23. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9:511-44.
24. Leroy A, Humbert G, Oksenhendler G, Fillastre JP. Pharmacokinetics of aminoglycosides in subjects with normal and impaired renal function. Antibiot Chemother 1978; 25:163-80.